These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 28382958)

  • 21. Chronic Nebivolol Treatment Suppresses Endothelin-1-Mediated Vasoconstrictor Tone in Adults With Elevated Blood Pressure.
    Diehl KJ; Stauffer BL; Dow CA; Bammert TD; Brunjes DL; Greiner JJ; DeSouza CA
    Hypertension; 2016 Jun; 67(6):1196-204. PubMed ID: 27113048
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protective effects of nebivolol and reversal of endothelial dysfunction in diabetes associated with hypertension.
    Georgescu A; Popov D; Dragan E; Dragomir E; Badila E
    Eur J Pharmacol; 2007 Sep; 570(1-3):149-58. PubMed ID: 17612521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension.
    Lefebvre J; Poirier L; Poirier P; Turgeon J; Lacourciere Y
    Br J Clin Pharmacol; 2007 May; 63(5):575-82. PubMed ID: 17094780
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Different influences on central and peripheral pulse pressure, aortic wave reflections and pulse wave velocity of three different types of antihypertensive drugs.
    Polónia J; Barbosa L; Silva JA; Maldonado J
    Rev Port Cardiol; 2003 Dec; 22(12):1485-92. PubMed ID: 15008064
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of beta-1-blocker, nebivolol, on central aortic pressure and arterial stiffness in patients with essential hypertension.
    Soanker R; Naidu MU; Raju SB; Prasad AK; Rao TR
    Indian J Pharmacol; 2012 May; 44(3):407-11. PubMed ID: 22701257
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial.
    Weiss RJ; Stapff M; Lin Y
    Am J Cardiovasc Drugs; 2013 Apr; 13(2):129-40. PubMed ID: 23519546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of antihypertensive drugs on central blood pressure beyond peripheral blood pressure. Part II: Evidence for specific class-effects of antihypertensive drugs on pressure amplification.
    Protogerou AD; Stergiou GS; Vlachopoulos C; Blacher J; Achimastos A
    Curr Pharm Des; 2009; 15(3):272-89. PubMed ID: 19149618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential Metabolic Effects of Beta-Blockers: an Updated Systematic Review of Nebivolol.
    Marketou M; Gupta Y; Jain S; Vardas P
    Curr Hypertens Rep; 2017 Mar; 19(3):22. PubMed ID: 28283926
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of nebivolol on renal nitric oxide availability and tubular function in patients with essential hypertension.
    Mose FH; Jensen JM; Therwani S; Mortensen J; Hansen AB; Bech JN; Pedersen EB
    Br J Clin Pharmacol; 2015 Sep; 80(3):425-35. PubMed ID: 25778445
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vascular Aging and Central Aortic Blood Pressure: From Pathophysiology to Treatment.
    Battistoni A; Michielon A; Marino G; Savoia C
    High Blood Press Cardiovasc Prev; 2020 Aug; 27(4):299-308. PubMed ID: 32572706
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nebivolol/valsartan: Fixed-dose combination for treatment of hypertension.
    Paton DM
    Drugs Today (Barc); 2017 Jan; 53(1):19-26. PubMed ID: 28387384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cuff-Based Oscillometric Central and Brachial Blood Pressures Obtained Through ABPM are Similarly Associated with Renal Organ Damage in Arterial Hypertension.
    Fernández-Llama P; Pareja J; Yun S; Vázquez S; Oliveras A; Armario P; Blanch P; Calero F; Sierra C; de la Sierra A
    Kidney Blood Press Res; 2017; 42(6):1068-1077. PubMed ID: 29197874
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Critical Review of Nebivolol and its Fixed-Dose Combinations in the Treatment of Hypertension.
    Cicero AFG; Kuwabara M; Borghi C
    Drugs; 2018 Nov; 78(17):1783-1790. PubMed ID: 30426333
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of renin-angiotensin-aldosterone system inhibitors and beta-blockers on markers of arterial stiffness.
    Koumaras C; Tziomalos K; Stavrinou E; Katsiki N; Athyros VG; Mikhailidis DP; Karagiannis A
    J Am Soc Hypertens; 2014 Feb; 8(2):74-82. PubMed ID: 24139833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Arterial stiffness and central hemodynamics in treated hypertensive subjects according to brachial blood pressure classification.
    Safar ME; Blacher J; Protogerou A; Achimastos A
    J Hypertens; 2008 Jan; 26(1):130-7. PubMed ID: 18090550
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men.
    Brixius K; Middeke M; Lichtenthal A; Jahn E; Schwinger RH
    Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):327-31. PubMed ID: 17324145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nebivolol: a third-generation beta-blocker for hypertension.
    Cheng JW
    Clin Ther; 2009 Mar; 31(3):447-62. PubMed ID: 19393838
    [TBL] [Abstract][Full Text] [Related]  

  • 38. β-Blockers in patients with intermittent claudication and arterial hypertension: results from the nebivolol or metoprolol in arterial occlusive disease trial.
    Espinola-Klein C; Weisser G; Jagodzinski A; Savvidis S; Warnholtz A; Ostad MA; Gori T; Munzel T
    Hypertension; 2011 Aug; 58(2):148-54. PubMed ID: 21646599
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of high central blood pressure in young with isolated systolic hypertension.
    Radchenko GD; Torbas OO; Sirenko YM
    Vasc Health Risk Manag; 2016; 12():321-8. PubMed ID: 27536127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis.
    Van Bortel LM; Fici F; Mascagni F
    Am J Cardiovasc Drugs; 2008; 8(1):35-44. PubMed ID: 18303936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.